Week in Review: Sinopharm Raises $716 Million in Secondary Offering
November 29, 2014 at 02:30 AM EST
Sinopharm, China's largest drug distributor, raised $716 million by placing 199 million new shares with institutional investors; Ally Bridge Group, a Hong Kong-US VC firm, participated in the $8.3 million funding of a Munich preclinical biotech, Pieris; Haiyin Capital made a $5 million investment in the C funding round of Seattle medical device company Cerevast; CARsgen of Shanghai completed a Series A funding of an undisclosed amount led by BVCF to advance its cancer immunotherapy program; Nanjing Frontier Biotech gained global rights to a novel topical patch for acute and chronic pain management from ABsize of Japan; and Actavis, which nailed down a $66 billion deal to acquire Allergan and its Botox cosmetic drug, announced it will target China with its expanded portfolio -- after exiting the China market earlier in 2014. More details.... Stock Symbols: (HK: 1099) (NYSE: ACT) Share this with colleagues: // //